<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 25 Oct 2024 00:52:02 +0000</lastbuilddate>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>HFpEF's Fuel Flaw: Impaired Fatty Acid Oxidation Stalls Mitophagy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39446882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 25;135(10):1018-1020. doi: 10.1161/CIRCRESAHA.124.325501. Epub 2024 Oct 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39446882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39446882</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325501>10.1161/CIRCRESAHA.124.325501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39446882</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Åsa B Gustafsson</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>HFpEF's Fuel Flaw: Impaired Fatty Acid Oxidation Stalls Mitophagy</dc:title>
<dc:identifier>pmid:39446882</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325501</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39446881/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 25;135(10):971. doi: 10.1161/RES.0000000000000697. Epub 2024 Oct 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39446881/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39446881</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000697>10.1161/RES.0000000000000697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39446881</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-24</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:39446881</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000697</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39446880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 25;135(10):972-973. doi: 10.1161/RES.0000000000000698. Epub 2024 Oct 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39446880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39446880</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000698>10.1161/RES.0000000000000698</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39446880</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-24</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39446880</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000698</dc:identifier>
</item>
<item>
<title>Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrosis is one of the main manifestations of atrial cardiomyopathy, an array of electrical, mechanical and structural alterations associated with atrial fibrillation (AF), stroke and heart failure. Atrial fibrosis can be both a cause and a consequence of AF and, once present, it accelerates the progression of AF. The pathophysiological mechanisms leading to atrial fibrosis are diverse and include stretch-induced activation of fibroblasts, systemic inflammatory processes, activation of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 23. doi: 10.1038/s41569-024-01088-w. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrosis is one of the main manifestations of atrial cardiomyopathy, an array of electrical, mechanical and structural alterations associated with atrial fibrillation (AF), stroke and heart failure. Atrial fibrosis can be both a cause and a consequence of AF and, once present, it accelerates the progression of AF. The pathophysiological mechanisms leading to atrial fibrosis are diverse and include stretch-induced activation of fibroblasts, systemic inflammatory processes, activation of coagulation factors and fibrofatty infiltrations. Importantly, atrial fibrosis can occur in different forms, such as reactive and replacement fibrosis. The diversity of atrial fibrosis mechanisms and patterns depends on sex, age and comorbidity profile, hampering the development of therapeutic strategies. In addition, the presence and severity of comorbidities often change over time, potentially causing temporal changes in the mechanisms underlying atrial fibrosis development. This Review summarizes the latest knowledge on the molecular and cellular mechanisms of atrial fibrosis, its association with comorbidities and the sex-related differences. We describe how the various patterns of atrial fibrosis translate into electrophysiological mechanisms that promote AF, and critically appraise the clinical applicability and limitations of diagnostic tools to quantify atrial fibrosis. Finally, we provide an overview of the newest therapeutic interventions under development and discuss relevant knowledge gaps related to the association between clinical manifestations and pathological mechanisms of atrial fibrosis and to the translation of this knowledge to a clinical setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443702</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01088-w>10.1038/s41569-024-01088-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443702</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Sander Verheule</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches</dc:title>
<dc:identifier>pmid:39443702</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01088-w</dc:identifier>
</item>
<item>
<title>OpenEP and EP Workbench for electrophysiology data analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 23. doi: 10.1038/s41569-024-01092-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443701/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443701</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01092-0>10.1038/s41569-024-01092-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443701</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Neil Bodagh</dc:creator>
<dc:creator>Steven E Williams</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>OpenEP and EP Workbench for electrophysiology data analysis</dc:title>
<dc:identifier>pmid:39443701</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01092-0</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1772. doi: 10.1016/j.jacc.2024.09.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443023</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.026>10.1016/j.jacc.2024.09.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443023</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443023</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.026</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1772. doi: 10.1016/j.jacc.2024.09.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443022</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.025>10.1016/j.jacc.2024.09.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443022</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443022</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.025</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1771. doi: 10.1016/j.jacc.2024.08.055.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.055>10.1016/j.jacc.2024.08.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443021</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.055</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1771. doi: 10.1016/j.jacc.2024.09.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443020</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.024>10.1016/j.jacc.2024.09.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443020</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443020</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.024</dc:identifier>
</item>
<item>
<title>Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>Low-dose aspirin remains the most commonly used antiplatelet agent among patients with atherosclerotic cardiovascular disease. Aspirin hypersensitivity occurs in 1% to 5% of patients and is among the most frequent causes for prohibiting the use of aspirin, posing a significant dilemma on how to manage these patients in clinical practice. Aspirin hypersensitivity is often misinterpreted and confused with aspirin intolerance, with treatment approaches being often unclear and lacking specific...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1748-1766. doi: 10.1016/j.jacc.2024.05.084.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Low-dose aspirin remains the most commonly used antiplatelet agent among patients with atherosclerotic cardiovascular disease. Aspirin hypersensitivity occurs in 1% to 5% of patients and is among the most frequent causes for prohibiting the use of aspirin, posing a significant dilemma on how to manage these patients in clinical practice. Aspirin hypersensitivity is often misinterpreted and confused with aspirin intolerance, with treatment approaches being often unclear and lacking specific recommendations. Aspirin desensitization and low-dose aspirin challenge have emerged as pragmatic, effective, and safe approaches in patients with suspected or confirmed aspirin hypersensitivity who require aspirin therapy, but they are underused systematically in clinical practice. Furthermore, there is confusion over alternative antiplatelet agents to be used in these patients. The pathophysiological mechanisms and classification of aspirin hypersensitivity, as well as alternative strategies and practical algorithms to overcome the need for aspirin use in patients with atherosclerotic cardiovascular disease with suspected aspirin hypersensitivity, are discussed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443019</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.084>10.1016/j.jacc.2024.05.084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443019</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Mattia Galli</dc:creator>
<dc:creator>Gabriele Cortellini</dc:creator>
<dc:creator>Giovanni Occhipinti</dc:creator>
<dc:creator>Roberta Rossini</dc:creator>
<dc:creator>Antonino Romano</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39443019</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.084</dc:identifier>
</item>
<item>
<title>Using Artificial Intelligence to Derive Environmental Drivers of Cardiovascular Risk: Is it Intelligent Enough?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1745-1747. doi: 10.1016/j.jacc.2024.09.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.014>10.1016/j.jacc.2024.09.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443018</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter James</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Artificial Intelligence to Derive Environmental Drivers of Cardiovascular Risk: Is it Intelligent Enough?</dc:title>
<dc:identifier>pmid:39443018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.014</dc:identifier>
</item>
<item>
<title>AI-Facilitated Assessment of Built Environment Using Neighborhood Satellite Imagery and Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AI-enhanced satellite images of the built environment were linked to MACE risk, independently of traditional risk factors and CAC, but this was influenced by social determinants of health, represented by SVI. Satellite image-based assessment of the built environment may provide a rapid scalable integrative approach, warranting further exploration for enhanced risk prediction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1733-1744. doi: 10.1016/j.jacc.2024.08.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Built environment affects cardiovascular health, but comprehensive assessment in a scalable fashion, for population health and resource allocation, is constrained by limitations of current microscale measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to investigate the association between satellite image-based environment and risk of major adverse cardiovascular events (MACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a pretrained deep neural network, features depicting the built environment from Google Satellite Imagery (GSI) around 64,230 patients in Northern Ohio undergoing coronary artery calcium (CAC) scoring were extracted. Elastic net regularized Cox proportional hazards models identified associations of GSI features with MACE risk (defined as myocardial infarction, stroke, heart failure, or death). A composite GSI risk score was constructed using features that demonstrated nonzero coefficients in the elastic net model. We assessed association of this score with MACE risk, after adjusting for CAC scores and the social vulnerability index (SVI). Its interactions with CAC scores were also examined in subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Adjusting for CAC and traditional risk factors, the GSI risk score was significantly associated with higher MACE risk (HR: 2.67; 95% CI: 1.63-4.38; P &lt; 0.001). However, adding SVI reduced this association to nonsignificance (HR: 1.54; 95% CI: 0.91-2.60; P = 0.11). Patients in the highest quartile (Q4) of GSI risk score had a 56% higher observed risk of MACE (HR: 1.56; 95% CI: 1.32-1.86; P &lt; 0.005) compared with the lowest quartile (Q1). The GSI risk score had the strongest association with MACE risk in patients with CAC = 0. This association was attenuated, but remained significant, with higher CAC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AI-enhanced satellite images of the built environment were linked to MACE risk, independently of traditional risk factors and CAC, but this was influenced by social determinants of health, represented by SVI. Satellite image-based assessment of the built environment may provide a rapid scalable integrative approach, warranting further exploration for enhanced risk prediction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.053>10.1016/j.jacc.2024.08.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443017</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Pedro Rafael Vieira de Oliveira Salerno</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Santosh Kumar Sirasapalli</dc:creator>
<dc:creator>Mohamed H E Makhlouf</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Skanda Moorthy</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>AI-Facilitated Assessment of Built Environment Using Neighborhood Satellite Imagery and Cardiovascular Risk</dc:title>
<dc:identifier>pmid:39443017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.053</dc:identifier>
</item>
<item>
<title>The Long Pathway to Improving Clinical Decisions With Better Risk Markers: Recurrent Thrombosis After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1730-1732. doi: 10.1016/j.jacc.2024.08.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.050>10.1016/j.jacc.2024.08.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443016</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason H Wasfy</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Long Pathway to Improving Clinical Decisions With Better Risk Markers: Recurrent Thrombosis After Myocardial Infarction</dc:title>
<dc:identifier>pmid:39443016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.050</dc:identifier>
</item>
<item>
<title>Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Quantifying pFCG identifies patients at higher and lower risk of subsequent cardiovascular events. This prognostic information will be useful in clinical decisions regarding the intensity and duration of antiplatelet therapy. (Assessment of Individual Risk of Cardiovascular Events by Platelet FcγRIIa; NCT05175261).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1721-1729. doi: 10.1016/j.jacc.2024.08.051.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A previous single-center study of patients with myocardial infarction (MI) showed that platelet FcγRIIa (pFCG) can distinguish patients at higher and lower risk of subsequent MI, stroke, and death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors performed an 800-patient 25-center study to validate the prognostic implications of pFCG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with type 1 MI (ST-segment elevation and non-ST-segment elevation) were enrolled in a prospective noninterventional trial during their index hospitalization. Enrolled patients had at least 2 of the following characteristics: age ≥65 years, multivessel coronary artery disease, previous MI, chronic kidney disease, or diabetes mellitus. Flow cytometry was used to quantify pFCG at a core laboratory. A predefined threshold was used to identify high and low pFCG. Patients were queried every 6 months by telephone with a standardized questionnaire. Events were confirmed by review of medical records.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Treatment with antithrombotic therapy (aspirin, P2Y<sub>12</sub> inhibitors, and anticoagulants) was similar in patients with high and low pFCG. The primary composite endpoint (MI, stroke, death) occurred more frequently in patients with high pFCG (HR: 2.09; 95% CI: 1.34-3.26; P = 0.001). Among individual components of the composite, both death (HR: 2.57; 95% CI: 1.50-4.40; P = 0.001) and MI (HR: 3.24; 95% CI: 1.64-6.37; P = 0.001) were more frequent in patients with high pFCG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Quantifying pFCG identifies patients at higher and lower risk of subsequent cardiovascular events. This prognostic information will be useful in clinical decisions regarding the intensity and duration of antiplatelet therapy. (Assessment of Individual Risk of Cardiovascular Events by Platelet FcγRIIa; NCT05175261).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.051>10.1016/j.jacc.2024.08.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443015</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>David J Schneider</dc:creator>
<dc:creator>Sean R McMahon</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Alexander Fanaroff</dc:creator>
<dc:creator>Homam Ibrahim</dc:creator>
<dc:creator>Patrick K Hohl</dc:creator>
<dc:creator>Brett L Wanamaker</dc:creator>
<dc:creator>Mark B Effron</dc:creator>
<dc:creator>Peter M DiBattiste</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction</dc:title>
<dc:identifier>pmid:39443015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.051</dc:identifier>
</item>
<item>
<title>Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1718-1720. doi: 10.1016/j.jacc.2024.09.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443014</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.013>10.1016/j.jacc.2024.09.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443014</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Sunil V Badve</dc:creator>
<dc:creator>Clare Arnott</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron</dc:title>
<dc:identifier>pmid:39443014</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.013</dc:identifier>
</item>
<item>
<title>Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations, suggesting that correcting iron deficiency might increase resistance or resilience to a broad range of problems that cause hospitalizations in patients with heart failure. (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency; NCT02642562).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1704-1717. doi: 10.1016/j.jacc.2024.08.052.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure and iron deficiency have diverse causes for hospitalization and death that might be affected by iron repletion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to explore causes of hospitalizations and deaths in a randomized trial (IRONMAN) of heart failure comparing intravenous ferric derisomaltose (FDI) (n = 568) and usual care (n = 569).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with heart failure, left ventricular ejection fraction ≤45%, and either transferrin saturation &lt;20% or serum ferritin &lt;100 μg/L were enrolled. Median follow-up was 2.7 years (Q1-Q3: 1.8-3.6 years). A committee adjudicated the main and contributory causes of unplanned hospitalizations and deaths. RRs (rate ratios) for selected recurrent events with 95% CIs are also reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with usual care, patients randomized to FDI had fewer unplanned hospitalizations (RR: 0.83; 95% CI: 0.71-0.97; P = 0.02), with similar reductions in cardiovascular (RR: 0.83; 95% CI: 0.69-1.01) and noncardiovascular (RR: 0.83; 95% CI: 0.67-1.03) hospitalizations, as well as hospitalizations for heart failure (RR: 0.78; 95% CI: 0.60-1.00), respiratory disease (RR: 0.70; 95% CI: 0.53-0.97), or infection (RR: 0.82; 95% CI: 0.66-1.03). Heart failure was the main cause for 26% of hospitalizations and contributed to or complicated a further 12%. Infection caused or contributed to 38% of all hospitalizations, including 27% of heart failure hospitalizations. Patterns of cardiovascular and all-cause mortality were similar for patients assigned to FDI or usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations, suggesting that correcting iron deficiency might increase resistance or resilience to a broad range of problems that cause hospitalizations in patients with heart failure. (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency; NCT02642562).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39443013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.052>10.1016/j.jacc.2024.08.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443013</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Pierpaolo Pellicori</dc:creator>
<dc:creator>Fraser J Graham</dc:creator>
<dc:creator>Rebecca Lane</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Fozia Ahmed</dc:creator>
<dc:creator>Iain B Squire</dc:creator>
<dc:creator>Andrew Ludman</dc:creator>
<dc:creator>Alan Japp</dc:creator>
<dc:creator>Abdallah Al-Mohammad</dc:creator>
<dc:creator>Andrew L Clark</dc:creator>
<dc:creator>Ben Szwejkowski</dc:creator>
<dc:creator>Chris Critoph</dc:creator>
<dc:creator>Victor Chong</dc:creator>
<dc:creator>Rebekah Schiff</dc:creator>
<dc:creator>Thuraia Nageh</dc:creator>
<dc:creator>Jason Glover</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Elizabeth A Thomson</dc:creator>
<dc:creator>Michele Robertson</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Philip A Kalra</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>IRONMAN Study Group</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure</dc:title>
<dc:identifier>pmid:39443013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.052</dc:identifier>
</item>
<item>
<title>Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39441603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this genetic association study, Black individuals with HTN at a lower genetic risk of elevated BP experienced an approximately 3.5 mm Hg-greater response to chlorthalidone compared with those at an intermediate genetic risk of elevated BP. SBP PRS may also identify individuals with HTN harboring a higher risk of treatment-resistant HTN. Overall, SBP PRS demonstrates potential to identify those who may have greater benefit from chlorthalidone, but future research is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 23. doi: 10.1001/jamacardio.2024.3649. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The clinical utility of polygenic risk scores (PRS) for blood pressure (BP) response to antihypertensive treatment (AHT) has not been elucidated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the ability of a systolic BP (SBP) PRS to predict AHT response and apparent treatment-resistant hypertension (aTRH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Genetics of Hypertension Associated Treatments (GenHAT) study was an ancillary pharmacogenomic study to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT, which enrolled participants aged 55 years or older with hypertension (HTN) starting in February 1994, completed follow-up in March 2002. The current study was conducted from a subset of Black GenHAT participants randomized to the treatment groups of either chlorthalidone (n = 3745) or lisinopril (n = 2294), with genetic data available from a prior genetic association study. The current study's objective was to examine the association of the SBP PRS to AHT response over 6 months, as well as to examine the predictive accuracy of the SBP PRS with aTRH. The current analysis took place in February 2023, with additional analyses conducted in July 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: An SBP PRS (comprising 1 084 157 genetic variants) stratified as quintiles and per SD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was change in SBP (ΔSBP) and diastolic BP (ΔDBP) over 6 months. aTRH was defined as the use of 3 AHTs with uncontrolled HTN at year 3 of follow-up or taking 4 or more AHTs at year 3 of follow-up, regardless of BP. Baseline demographics were compared across PRS quintiles using Kruskal-Wallis or χ2 tests as appropriate. The least-square means of BP response were calculated through multivariable adjusted linear regression, and multivariable adjusted logistic regression was used to calculate the odds ratios and 95% confidence intervals for aTRH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3745 Black GenHAT participants randomized to chlorthalidone treatment, median (IQR) participant age was 65 (60-71) years, and 2064 participants (55.1%) were female. Each increasing quintile of the SBP PRS from 1 to 5 was associated with a reduced BP response to treatment over 6 months. Participants in the lowest quintile experienced a mean ΔSBP of -10.01 mm Hg (95% CI, -11.11 to -8.90) compared to -6.57 mm Hg (95% CI, -7.67 to -5.48) for participants in the median quintile. No associations were observed between the SBP PRS and BP response to lisinopril. Participants in the highest PRS quintile had 67% higher odds of aTRH compared to those in the median quintile (odds ratio, 1.67; 95% CI, 1.19-2.36). These associations were independently validated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this genetic association study, Black individuals with HTN at a lower genetic risk of elevated BP experienced an approximately 3.5 mm Hg-greater response to chlorthalidone compared with those at an intermediate genetic risk of elevated BP. SBP PRS may also identify individuals with HTN harboring a higher risk of treatment-resistant HTN. Overall, SBP PRS demonstrates potential to identify those who may have greater benefit from chlorthalidone, but future research is needed to determine if PRS can inform initiation and choice of treatment among individuals with HTN.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39441603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39441603</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3649>10.1001/jamacardio.2024.3649</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39441603</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicole D Armstrong</dc:creator>
<dc:creator>Vinodh Srinivasasainagendra</dc:creator>
<dc:creator>Amit Patki</dc:creator>
<dc:creator>Alana C Jones</dc:creator>
<dc:creator>Vibhu Parcha</dc:creator>
<dc:creator>Akhil Pampana</dc:creator>
<dc:creator>Ulrich Broeckel</dc:creator>
<dc:creator>Leslie A Lange</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Nita A Limdi</dc:creator>
<dc:creator>Hemant K Tiwari</dc:creator>
<dc:creator>Marguerite R Irvin</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response</dc:title>
<dc:identifier>pmid:39441603</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3649</dc:identifier>
</item>
<item>
<title>Precision Medicine to Guide Blood Pressure Control?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39441574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 23. doi: 10.1001/jamacardio.2024.3662. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39441574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39441574</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3662>10.1001/jamacardio.2024.3662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39441574</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Precision Medicine to Guide Blood Pressure Control?</dc:title>
<dc:identifier>pmid:39441574</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3662</dc:identifier>
</item>
<item>
<title>Salt Responsive Gut Microbiota Induces Sex Specific Blood Pressure Changes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39440438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We uncovered a novel sex-specific mechanism in the gut microbiota-mediated tryptophan-indole pathway in blood pressure regulation. Salt tipped the tryptophan metabolism between the host and gut microbiota in a sex-dependent manner. Our study provides evidence for a novel concept that gut microbiota and its metabolism play sex-specific roles in the development of salt-sensitive hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 23. doi: 10.1161/CIRCRESAHA.124.325056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tryptophan metabolism is important in blood pressure regulation. The tryptophan-indole pathway is exclusively mediated by the gut microbiota. ACE2 (angiotensin-converting enzyme 2) participates in tryptophan absorption, and a lack of ACE2 leads to changes in the gut microbiota. The gut microbiota has been recognized as a regulator of blood pressure. Furthermore, there is ample evidence for sex differences in the gut microbiota. However, it is unclear whether such sex differences impact blood pressure differentially through the tryptophan-indole pathway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To study the sex-specific mechanisms of gut microbiota-mediated tryptophan-indole pathway in hypertension, we generated a novel rat model with Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9)-targeted deletion of <i>Ace2</i> in the Dahl salt-sensitive rat. Cecal microbiota transfers from donors of both sexes to female S recipients were performed. Also, Dahl salt-sensitive rats of both sexes were orally gavaged with indole to investigate blood pressure response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The female gut microbiota and its tryptophan-indole pathway exhibited greater buffering capacity when exposed to tryptophan, due to <i>Ace2</i> deficiency, and salt. In contrast, the male gut microbiota and its tryptophan-indole pathway were more vulnerable. Female rats with male cecal microbiota responded to salt with a higher blood pressure increase. Indole, a tryptophan-derived metabolite produced by gut bacteria, increased blood pressure in male but not in female rats. Moreover, salt altered host-mediated tryptophan metabolism, characterized by reduced serum serotonin of both sexes and higher levels of kynurenine derivatives in the females.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We uncovered a novel sex-specific mechanism in the gut microbiota-mediated tryptophan-indole pathway in blood pressure regulation. Salt tipped the tryptophan metabolism between the host and gut microbiota in a sex-dependent manner. Our study provides evidence for a novel concept that gut microbiota and its metabolism play sex-specific roles in the development of salt-sensitive hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39440438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39440438</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325056>10.1161/CIRCRESAHA.124.325056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39440438</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pritam Bardhan</dc:creator>
<dc:creator>Xue Mei</dc:creator>
<dc:creator>Ngoc Khanh Lai</dc:creator>
<dc:creator>Blair Mell</dc:creator>
<dc:creator>Ramakumar Tummala</dc:creator>
<dc:creator>Sachin Aryal</dc:creator>
<dc:creator>Ishan Manandhar</dc:creator>
<dc:creator>Hyeongu Hwang</dc:creator>
<dc:creator>Tania Akter Jhuma</dc:creator>
<dc:creator>Rohit R Atluri</dc:creator>
<dc:creator>Jun Kyoung</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Bina Joe</dc:creator>
<dc:creator>Hong-Bao Li</dc:creator>
<dc:creator>Tao Yang</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt Responsive Gut Microbiota Induces Sex Specific Blood Pressure Changes</dc:title>
<dc:identifier>pmid:39440438</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325056</dc:identifier>
</item>
<item>
<title>Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39440421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: New-onset LBBB after SAVR is associated with increased all-cause mortality during follow-up, and is more frequent complication in BAV AS patients compared with TAV-AS patients. BAV-AS patients with fusion of the right- and non-coronary cusps have an increased risk for conduction disturbances after SAVR. This should be taken into consideration when managing these patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 23. doi: 10.1161/CIRCULATIONAHA.124.070753. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively). Additionally, the study included stratification of BAV patients according to subtype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this cohort study, the incidence of postoperative third-degree atrioventricular (AV) block with subsequent permanent pacemaker requirement and new-onset left bundle-branch block (LBBB) was investigated in 1147 consecutive patients without preoperative conduction disorder who underwent isolated SAVR (with or without ascending aortic surgery) between January 1, 2005, and December 31, 2022. The groups were stratified by aortic valve morphology (BAV, n=589; TAV, n=558). The outcomes of interests were new-onset third-degree AV block or new-onset LBBB during the index hospitalization. The impact of new-onset postoperative conduction disturbances on survival was investigated in BAV-AS and TAV-AS patients during a median follow-up of 8.2 years. BAV morphology was further categorized according to the Sievers and Schmidtke classification system (possible in 307 BAV-AS patients) to explore association between BAV subtypes and new-onset conduction disturbances after SAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The overall incidence of third-degree AV block and new-onset LBBB after SAVR was 4.5% and 7.8%, respectively. BAV-AS patients had a higher incidence of both new-onset third-degree AV block (6.5% versus 2.5%; <i>P</i>=0.001) and new-onset LBBB (9.7% versus 5.7%; <i>P</i>=0.013) compared with TAV-AS patients. New-onset LBBB was associated with an increased all-cause mortality during follow-up (adjusted hazard ratio, 1.60 [95% CI, 1.12-2.30]; <i>P</i>=0.011), whereas new-onset third-degree AV block was not associated with worse prognosis. Subgroup analysis of the BAV cohort revealed that BAV-AS patients with fusion of the right- and non-coronary cusps had the highest risk of new-onset third-degree AV block (adjusted odds ratio [aOR], 8.33 [95% CI, 3.31-20.97]; <i>P</i>&lt;0.001, with TAV as reference group) and new-onset LBBB (aOR, 4.03 [95% CI, 1.84-8.82]; <i>P</i>&lt;0.001, with TAV as reference group), whereas no significant association was observed for the other BAV subtypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: New-onset LBBB after SAVR is associated with increased all-cause mortality during follow-up, and is more frequent complication in BAV AS patients compared with TAV-AS patients. BAV-AS patients with fusion of the right- and non-coronary cusps have an increased risk for conduction disturbances after SAVR. This should be taken into consideration when managing these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39440421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39440421</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070753>10.1161/CIRCULATIONAHA.124.070753</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39440421</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Johan O Wedin</dc:creator>
<dc:creator>Viktor Näslund</dc:creator>
<dc:creator>Sergey Rodin</dc:creator>
<dc:creator>Oscar E Simonson</dc:creator>
<dc:creator>Frank A Flachskampf</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Elisabeth Ståhle</dc:creator>
<dc:creator>Karl-Henrik Grinnemo</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis</dc:title>
<dc:identifier>pmid:39440421</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070753</dc:identifier>
</item>
<item>
<title>P-stalk ribosomes act as master regulators of cytokine-mediated processes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39437780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241024205201&amp;v=2.18.0.post9+e462414
      <description>Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of ribosomes defined by the presence of the P-stalk. We show that P-stalk ribosomes (PSRs) are formed in response to cytokines linked to tumor immunity, and this is at least partially mediated by P-stalk phosphorylation. PSRs are involved in the preferential translation of mRNAs vital for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 14:S0092-8674(24)01139-5. doi: 10.1016/j.cell.2024.09.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of ribosomes defined by the presence of the P-stalk. We show that P-stalk ribosomes (PSRs) are formed in response to cytokines linked to tumor immunity, and this is at least partially mediated by P-stalk phosphorylation. PSRs are involved in the preferential translation of mRNAs vital for the cytokine response via the more efficient translation of transmembrane domains of receptor molecules involved in cytokine-mediated processes. Importantly, loss of the PSR inhibits CD8+ T cell recognition and killing, and inhibitory cytokines like transforming growth factor β (TGF-β) hinder PSR formation, suggesting that the PSR is a central regulatory hub upon which multiple signals converge. Thus, the PSR is an essential mediator of the cellular rewiring that occurs following cytokine exposure via the translational regulation of this process.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39437780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241024205201&v=2.18.0.post9+e462414">39437780</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.039>10.1016/j.cell.2024.09.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39437780</guid>
<pubDate>Tue, 22 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna Dopler</dc:creator>
<dc:creator>Ferhat Alkan</dc:creator>
<dc:creator>Yuval Malka</dc:creator>
<dc:creator>Rob van der Kammen</dc:creator>
<dc:creator>Kelly Hoefakker</dc:creator>
<dc:creator>Daniel Taranto</dc:creator>
<dc:creator>Naz Kocabay</dc:creator>
<dc:creator>Iris Mimpen</dc:creator>
<dc:creator>Christel Ramirez</dc:creator>
<dc:creator>Elke Malzer</dc:creator>
<dc:creator>Olga I Isaeva</dc:creator>
<dc:creator>Mandy Kerkhoff</dc:creator>
<dc:creator>Anastasia Gangaev</dc:creator>
<dc:creator>Joana Silva</dc:creator>
<dc:creator>Sofia Ramalho</dc:creator>
<dc:creator>Liesbeth Hoekman</dc:creator>
<dc:creator>Maarten Altelaar</dc:creator>
<dc:creator>Roderick Beijersbergen</dc:creator>
<dc:creator>Leila Akkari</dc:creator>
<dc:creator>Jonathan Wilson Yewdell</dc:creator>
<dc:creator>Pia Kvistborg</dc:creator>
<dc:creator>William James Faller</dc:creator>
<dc:date>2024-10-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>P-stalk ribosomes act as master regulators of cytokine-mediated processes</dc:title>
<dc:identifier>pmid:39437780</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.039</dc:identifier>
</item>





























</channel>
</rss>